Hospital
Princeton Healthcare System, a New Jersey Non-Profit Corporation
Princeton Healthcare System, a New Jersey Non-Profit Corporation was paid $33.55M by Medicaid between Jan 2018 and Dec 2024, across 214 billing codes. Its largest line is 99285, emergency room visit (most serious) — 25% of everything it billed.
33Billing provider infoPRINCETON HEALTHCARE SYSTEM, A NEW JERSEY NON-PROFIT CORPORATION
PLAINSBORO, NJ 08536
PLAINSBORO, NJ 08536
33aNPI1689714255assigned 02/06/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$33.55M
24GClaims547,036
24DCodes billed214
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#45 of 93
Median peer was paid$30.60M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 67,489 | $6.04M | |
| 2019 | 64,965 | $6.15M | |
| 2020 | 53,747 | $3.80M | |
| 2021 | 69,677 | $3.92M | |
| 2022 | 101,780 | $4.90M | |
| 2023 | 110,992 | $5.08M | |
| 2024incomplete | 78,386 | $3.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 25% | 16,360 | 14,599 | $8.26M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 16,776 | 15,209 | $6.69M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 16,629 | 15,450 | $4.03M |
| G0378 | Hospital observation service, per hour | 8.8% | 5,141 | 3,872 | $2.95M |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | 6.8% | 11,534 | 986 | $2.30M |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | 4.7% | 7,904 | 862 | $1.57M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 2,553 | 2,338 | $1.25M |
| G0176 | Activity therapy, such as music, dance, art or play therapies not for recreation, related to the care and treatment of patient's disabling mental health problems, per session (45 minutes or more) | 2.7% | 2,930 | 507 | $908K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 4,150 | 3,738 | $522K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16,478 | 14,138 | $285K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,170 | 6,489 | $219K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,532 | 6,924 | $210K |
202 more codes
| OP370 | <1% | 1,328 | $206K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,186 | $203K |
| OP710 | <1% | 2,114 | $201K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,529 | $194K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,544 | $163K |
| 76830 | Ultrasound, transvaginal | <1% | 1,248 | $153K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,817 | $136K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,779 | $131K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 789 | $130K |
| 80053 | Comprehensive metabolic panel | <1% | 24,307 | $121K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,235 | $121K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,809 | $116K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,757 | $104K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 530 | $103K |
| 76801 | <1% | 734 | $100K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 336 | $96K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,262 | $82K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,991 | $81K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,324 | $78K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,279 | $69K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 820 | $66K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 615 | $65K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,182 | $64K |
| OP250 | <1% | 74,928 | $62K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 36,436 | $59K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,677 | $59K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,987 | $58K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 11,388 | $57K |
| 80320 | <1% | 2,230 | $57K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,987 | $54K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 267 | $49K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,710 | $46K |
| 93975 | <1% | 1,007 | $44K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,778 | $36K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,259 | $36K |
| 84484 | <1% | 7,126 | $34K | |
| 90837 | Psychotherapy session, about an hour | <1% | 52 | $30K |
| OP270 | <1% | 993 | $29K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,156 | $26K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 736 | $26K |
| 85027 | <1% | 11,589 | $24K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 692 | $24K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 556 | $23K |
| 59025 | Fetal non-stress test | <1% | 101 | $23K |
| 74018 | <1% | 1,085 | $21K | |
| 88142 | <1% | 384 | $21K | |
| 81001 | <1% | 8,282 | $20K | |
| 81025 | <1% | 9,031 | $19K | |
| 86769 | <1% | 2,171 | $19K | |
| 81003 | <1% | 8,793 | $19K | |
| 59050 | <1% | 63 | $19K | |
| 93971 | <1% | 227 | $17K | |
| 82948 | <1% | 4,067 | $17K | |
| 97162 | <1% | 707 | $17K | |
| 73030 | <1% | 574 | $17K | |
| 86850 | <1% | 2,381 | $16K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,283 | $15K |
| 87581 | <1% | 1,297 | $15K | |
| 87486 | <1% | 1,297 | $15K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 733 | $15K |
| OP229 | <1% | 288 | $15K | |
| 83690 | <1% | 6,258 | $14K | |
| 73564 | <1% | 455 | $14K | |
| 85610 | <1% | 7,468 | $14K | |
| 85730 | <1% | 6,620 | $14K | |
| 97161 | <1% | 447 | $14K | |
| 73610 | <1% | 568 | $13K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,967 | $13K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 800 | $13K |
| 73630 | <1% | 643 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,961 | $12K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 93 | $11K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,127 | $10K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 869 | $10K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 261 | $9K |
| 83735 | <1% | 3,556 | $9K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 433 | $9K |
| 76857 | <1% | 137 | $9K | |
| OP272 | <1% | 422 | $8K | |
| 84702 | <1% | 1,186 | $8K | |
| 87040 | <1% | 1,771 | $8K | |
| 83605 | <1% | 1,482 | $8K | |
| 72100 | <1% | 216 | $7K | |
| 73130 | <1% | 278 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,645 | $7K |
| 93976 | <1% | 63 | $7K | |
| 80061 | Lipid panel | <1% | 2,198 | $7K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 52 | $6K |
| 84703 | <1% | 1,792 | $6K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 681 | $6K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 737 | $6K |
| 86900 | <1% | 2,588 | $5K | |
| 87507 | <1% | 77 | $5K | |
| 85007 | <1% | 3,151 | $5K | |
| 87081 | <1% | 1,823 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 437 | $5K |
| 94664 | <1% | 410 | $5K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 116 | $5K |
| 83880 | <1% | 522 | $4K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 14 | $4K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 196 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,530 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 317 | $4K |
| 87186 | <1% | 884 | $4K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,484 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,677 | $3K |
| 87077 | <1% | 1,084 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,177 | $3K |
| 76770 | <1% | 27 | $3K | |
| 87631 | <1% | 132 | $3K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 79 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,731 | $3K |
| 93970 | <1% | 15 | $2K | |
| OP258 | <1% | 441 | $2K | |
| 90647 | <1% | 120 | $2K | |
| G0239 | Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitoring) | <1% | 371 | $2K |
| OP279 | <1% | 172 | $2K | |
| 86140 | <1% | 2,002 | $2K | |
| 85379 | <1% | 965 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 24 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 66 | $2K |
| 82962 | <1% | 1,887 | $2K | |
| 82550 | <1% | 709 | $2K | |
| 73110 | <1% | 101 | $2K | |
| 90715 | <1% | 295 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 781 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 767 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,026 | $1K |
| 80076 | <1% | 521 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,370 | $1K |
| OP259 | <1% | 1,556 | $1K | |
| 94799 | <1% | 109 | $943.26 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 25 | $845.70 |
| 73502 | <1% | 25 | $826.57 | |
| 86901 | <1% | 869 | $821.75 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 60 | $606.44 |
| 84100 | <1% | 752 | $599.00 | |
| 82607 | <1% | 368 | $598.39 | |
| 85651 | <1% | 766 | $516.10 | |
| 87563 | <1% | 35 | $510.11 | |
| 82728 | <1% | 200 | $473.00 | |
| 86803 | <1% | 106 | $448.60 | |
| 73090 | <1% | 15 | $428.18 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 275 | $396.40 |
| 80164 | <1% | 39 | $371.19 | |
| J3490 | Unclassified drugs | <1% | 455 | $364.61 |
| 83550 | <1% | 244 | $297.50 | |
| 83540 | <1% | 332 | $288.23 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 849 | $281.05 |
| 85652 | <1% | 363 | $267.28 | |
| 96376 | <1% | 17 | $244.98 | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 150 | $238.80 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 631 | $218.19 |
| 84439 | <1% | 166 | $213.59 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 352 | $211.44 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 667 | $204.05 |
| 87070 | <1% | 127 | $182.95 | |
| 97116 | <1% | 38 | $180.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 570 | $179.43 |
| OP762 | <1% | 73 | $170.49 | |
| OP255 | <1% | 38 | $161.60 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 873 | $159.12 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 150 | $158.79 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 873 | $149.41 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 34 | $138.09 |
| 82553 | <1% | 12 | $115.60 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 209 | $115.36 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 159 | $108.28 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 409 | $102.31 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 13 | $101.41 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 499 | $97.76 |
| 87807 | <1% | 34 | $96.52 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 375 | $87.47 |
| 73080 | <1% | 16 | $73.30 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 364 | $71.76 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 63 | $56.58 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 124 | $51.32 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 116 | $46.16 |
| 82746 | <1% | 16 | $46.12 | |
| J1815 | Injection, insulin, per 5 units | <1% | 126 | $45.64 |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 104 | $38.97 |
| 92551 | <1% | 39 | $36.04 | |
| 82570 | <1% | 118 | $35.50 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 81 | $29.86 |
| 84550 | <1% | 39 | $28.33 | |
| 82248 | <1% | 19 | $27.00 | |
| 87205 | <1% | 39 | $26.83 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 273 | $25.92 |
| 87147 | <1% | 40 | $24.15 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 54 | $20.01 |
| 82247 | <1% | 14 | $14.00 | |
| 99173 | <1% | 36 | $9.32 | |
| 86308 | <1% | 16 | $7.78 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 13 | $4.31 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 629 | $0.00 |
| 90461 | 0% | 264 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 53 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 46 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 40 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 17 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 48 | $0.00 |
| OP510 | 0% | 52 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVALLADARES, GUILLHERME (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Princeton Healthcare System, a New Jersey Non-Profit Corporation | Princeton, NJ | $74K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.